Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Uraemic toxins are considered to be emerging mortality risk factors in chronic kidney disease (CKD) patients. p-Cresol (a prototype protein-bound uraemic retention solute) has been shown to exert toxic effects in vitro. Recently, it has been demonstrated that p-cresol is present in plasma as its sulphate conjugate, p-cresylsulphate. The present study evaluated the distribution of free and total p-cresylsulphate and sought to determine whether these parameters were associated with vascular calcification, arterial stiffness and mortality risk in a cohort of CKD patients. METHODS: One hundred and thirty-nine patients (mean +/- SD age: 67 +/- 12; males: 60%) at different stages of CKD (8% at Stage 2, 26.5% at Stage 3, 26.5% at Stage 4, 7% at Stage 5 and 32% at Stage 5D) were enrolled in this study. RESULTS: Baseline total and free p-cresylsulphate presented an inverse relationship with renal function and were significantly associated with vascular calcification. During the study period (mean follow-up period: 779 +/- 185 days), 38 patients died [including 22 from cardiovascular (CV) causes]. In crude survival analyses, free (but not total) p-cresylsulphate was shown to be a predictor of overall and CV death. Higher free p-cresylsulphate levels (>0.051 mg/100 mL; median) were associated with mortality independently of well-known predictors of survival such as age, vascular calcification, anaemia and inflammation. CONCLUSIONS: Serum levels of free and total p-cresylsulphate (the main in vivo circulating metabolites of p-cresol) were elevated in later CKD stages. However, only free p-cresylsulphate seems to be a predictor of survival in CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Asmar, R., Benetos, A., Topouchian, J., Laurent, P., Pannier, B., Brisac, A.-M., Target, R., & Levy, B. I. (1995) · Hypertension · doi:10.1161/01.hyp.26.3.485 · Cited by 1,376
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Stevens, L. A., Coresh, J., Schmid, C. H., Feldman, H. I., Froissart, M., Kusek, J., Rossert, J., Van Lente, F., Bruce, R. D., Zhang, Y. (., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.018 · Cited by 1,037
Kauppila, L. I., Polak, J. F., Cupples, L. A., Hannan, M. T., Kiel, D. P., & Wilson, P. W. F. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00106-8 · Cited by 728
Chronic kidney disease as cause of cardiovascular morbidity and mortality
Vanholder, R., Massy, Z., Argiles, A., Spasovski, G., Verbeke, F., & Lameire, N. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh813 · Cited by 613
Self-citationThe uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair
Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., Berland, Y., & Brunet, P. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00399.x · Cited by 489
Self-citationBammens, B., Evenepoel, P., Keuleers, H., Verbeke, K., & Vanrenterghem, Y. (2006) · Kidney International · doi:10.1038/sj.ki.5000115 · Cited by 388
Free p-cresol is associated with cardiovascular disease in hemodialysis patients
Meijers, B. K. I., Bammens, B., De Moor, B., Verbeke, K., Vanrenterghem, Y., & Evenepoel, P. (2008) · Kidney International · doi:10.1038/ki.2008.31 · Cited by 315
Cited by
Normal and Pathologic Concentrations of Uremic Toxins
Duranton, F., Cohen, G., De Smet, R., Rodriguez, M., Jankowski, J., Vanholder, R., & Argiles, A. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121175 · Cited by 961
Self-citationThe Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate: A Systematic Review
Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V., & Glorieux, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101062 · Cited by 683
Self-citationEpidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
Wang, X., Yang, S., Li, S., Zhao, L., Hao, Y., Qin, J., Zhang, L., Zhang, C., Bian, W., Zuo, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319766 · Cited by 541
p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
Wu, I.-W., Hsu, K.-H., Lee, C.-C., Sun, C.-Y., Hsu, H.-J., Tsai, C.-J., Tzen, C.-Y., Wang, Y.-C., Lin, C.-Y., & Wu, M.-S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq580 · Cited by 510
Gryp, T., Vanholder, R., Vaneechoutte, M., & Glorieux, G. (2017) · Toxins · doi:10.3390/toxins9020052 · Cited by 417
Self-citationRole of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394
Self-citationWatanabe, H., Miyamoto, Y., Honda, D., Tanaka, H., Wu, Q., Endo, M., Noguchi, T., Kadowaki, D., Ishima, Y., Kotani, S., et al. (2013) · Kidney International · doi:10.1038/ki.2012.448 · Cited by 389
The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid
Dou, L., Sallée, M., Cerini, C., Poitevin, S., Gondouin, B., Jourde-Chiche, N., Fallague, K., Brunet, P., Calaf, R., Dussol, B., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121283 · Cited by 329
The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression
Meijers, B. K. I., & Evenepoel, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq818 · Cited by 328
Sun, C.-Y., Chang, S.-C., & Wu, M.-S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034026 · Cited by 310
The Impact of CKD on Uremic Toxins and Gut Microbiota
Rysz, J., Franczyk, B., Ławiński, J., Olszewski, R., Ciałkowska-Rysz, A., & Gluba-Brzózka, A. (2021) · Toxins · doi:10.3390/toxins13040252 · Cited by 307
Evenepoel, P., Poesen, R., & Meijers, B. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3527-x · Cited by 305
Sirich, T. L., Plummer, N. S., Gardner, C. D., Hostetter, T. H., & Meyer, T. W. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00490114 · Cited by 297
Protein nutrition and malnutrition in CKD and ESRD
Zha, Y., & Qian, Q. (2017) · Nutrients · doi:10.3390/nu9030208 · Cited by 292
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD
Schulman, G., Berl, T., Beck, G. J., Remuzzi, G., Ritz, E., Arita, K., Kato, A., & Shimizu, M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010042 · Cited by 282
Kovesdy, C. P., Kopple, J. D., & Kalantar-Zadeh, K. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.036418 · Cited by 281
Lin, C.-J., Wu, V., Wu, P.-C., & Wu, C.-J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132589 · Cited by 277
p-Cresyl Sulfate Promotes Insulin Resistance Associated with CKD
Koppe, L., Pillon, N. J., Vella, R. E., Croze, M. L., Pelletier, C. C., Chambert, S., Massy, Z., Glorieux, G., Vanholder, R., Dugenet, Y., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050503 · Cited by 270
Self-citationGut microbiome in chronic kidney disease: challenges and opportunities
Nallu, A., Sharma, S., Ramezani, A., Muralidharan, J., & Raj, D. (2017) · Translational Research · doi:10.1016/j.trsl.2016.04.007 · Cited by 255
The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores
Patel, K. P., Luo, F. J.-G., Plummer, N. S., Hostetter, T. H., & Meyer, T. W. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12491211 · Cited by 226
Urinary p-cresol in autism spectrum disorder
Persico, A. M., & Napolioni, V. (2013) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2012.09.002 · Cited by 189
Chiavaroli, L., Mirrahimi, A., Sievenpiper, J. L., Jenkins, D. J. A., & Darling, P. B. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.237 · Cited by 170
Metadata
- Authors
- Liabeuf, S., Barreto, D. V., Barreto, F. C., Meert, N., Glorieux, G., Schepers, E., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z. A., & on behalf of the European Uraemic Toxin Work Group (EUTox)
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-13
- Volume
- 25
- Issue
- 4
- Pages
- 1183-1191
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2101431807
- Cited by
- 431
- References
- 34
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.